Data Readout

Krystal's inhaled gene therapy for CF heads toward a 2026 Phase 1 readout

KB407, an inhaled herpesvirus-vector gene therapy for cystic fibrosis, targets a year-end 2026 readout after enrollment rose to 20 and the completion date slipped three years from its original mark.

By AppliedXLJuly 13, 2026Trial NCT05504837

Executive Summary

Krystal Biotech is running an early safety study of an inhaled gene therapy for cystic fibrosis, and has guided to results sometime in 2026, without yet disclosing what those results show.
The trial is built to answer a tolerability question, not to prove clinical benefit, so a 2026 readout will speak to how the regimen is handled before it speaks to whether it works.
The completion timeline has moved out substantially since the trial started, while enrollment has climbed back to its original target, a combination that reads as a program still generating data rather than one stalling out.
A platform-level FDA designation granted this year signals that Krystal's delivery technology, not just this single cystic fibrosis program, is accumulating regulatory recognition that could carry over to sibling candidates.
No gene therapy or other modality in cystic fibrosis shares KB407's specific mechanism, leaving this readout as a standalone data point rather than one measured against a direct rival.

The catalyst

Krystal Biotech said in its first-quarter 2026 results that it expects to report data from the KB407 open-label study before year-end 2026. The trial, registered as NCT05504837, is a Phase 1 study assessing KB407 for cystic fibrosis, using a modality the company describes as a genetically modified, non-replicating herpes simplex virus type 1 viral vector delivered by inhalation. The primary outcome measure is safety and tolerability, tracked through adverse-event frequency and severity, physical exams, vital signs, ECG, and clinical laboratory results. That design means the 2026 readout will establish how patients tolerate the therapy and at what dose, not whether it produces a durable clinical benefit. Krystal+1

Probability of Success

Endpoint Met91%

Completes61%

Clinical Significance25%

Regulatory42%

Trial mechanics

The study enrolls adults 18 and older with a confirmed cystic fibrosis diagnosis, and is structured around four experimental treatment arms with non-randomized allocation. Enrollment, listed as anticipated rather than actual, sits at 20 patients, up from a prior target of 12 set in 2023. The primary completion date has moved four times since the trial's first registration: from March 2024 to July 2024 in mid-2023, to June 2025 in early 2025, to December 2025 in August 2025, and most recently to December 1, 2026, alongside the enrollment increase in May 2026. The trial started dosing patients on June 30, 2023, and is currently listed as Recruiting. NCT05504837

Reading the enrollment increase

An enrollment increase in an early-phase trial ordinarily signals the sponsor adding cohorts or dose levels to answer more of the safety question, not distress. The rise back to the original target of 20, paired with the completion-date extension to accommodate that larger patient count, fits that pattern here. The trial's eligibility criteria have also been revised three times, a level of protocol churn typical of a Phase 1 dose-finding study still refining which patients qualify as cohorts advance. NCT05504837

The regulatory signal

In April 2026, the FDA granted platform technology designation covering KB407 for cystic fibrosis, alongside KB111 for hidradenitis suppurativa. Krystal's chief executive, Krish S. Krishnan, said in the company's first-quarter disclosure that "with three pipeline products receiving platform designation, each development milestone strengthens the regulatory dataset, which could accelerate future programs and potentially reduce development risk". That designation applies to the vector platform underlying multiple Krystal programs, not to KB407's cystic fibrosis data specifically, so its near-term relevance is to how efficiently future herpesvirus-vector candidates can advance rather than to this readout's outcome. Krystal

Competitive frame

Cystic fibrosis gene therapy is a field with modality precedent but no shared mechanism: 4D Molecular Therapeutics' 4D-710 and Spirovant Sciences' SP-101 are both in clinical testing and both target CFTR directly through gene therapy, while KB407's target is not characterized in available registry data, leaving it without a direct comparator on mechanism. The indication's dominant activity instead sits with small-molecule CFTR modulators from Vertex Pharmaceuticals, including a Phase 3 program for vanzacaftor, which represent the current standard of care rather than a competing gene-therapy approach. Given that no validated gene-therapy mechanism has yet reached late-stage development in cystic fibrosis, a KB407 readout that establishes a clean tolerability profile across the full dose range would be the result that lets the program advance toward efficacy testing. NCT05504837

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.